Dr. Muniz’s twenty-five-year scientific and business management career has spanned international, federal and local public health government organizations, large pharmaceutical and small biotechnology companies.
Dr. Muniz held several senior executive roles at Eli Lilly and Company (1995-2005), including Head of Worldwide Pharmacovigilance and Epidemiology, Cardiovascular Business Unit Leader, and Vice President of Global Oncology Clinical Development.
He joined Certara in 2014 from Kirax Corporation, where he served as President and CEO since 2005. In that role, he focused on acquiring, developing and commercializing innovative therapies for oncology, pain, inflammation, acute and supportive care.
Dr. Muniz earned an MD degree from the Autonomous University of Santo Domingo in the Dominican Republic, a PhD in Population Planning and International Health and an MS in Population Planning, both from the University of Michigan School of Public Health. Dr. Muniz is also a graduate of the Epidemic Intelligence Service Program and the Preventive Medicine Fellowship at the Centers for Disease Control and Prevention in Atlanta, Georgia.
Dr. Muniz was recently named as one of the PharmaVOICE 100 most inspirational “Commanders in Chief” leaders in the life-sciences industry.
Recently, Dr. Muniz co-authored the article Drug Development through Modeling and Simulation—the Business Case.
Click here to watch PharmaVOICE’s interview with Certara’s Donald Deieso and Edmundo Muniz, conducted at DIA 2016.